Physician profile
Jennifer Matro
NPI 1972765550
$19,348.91
in general payments reported to CMS, 2019-2025
10 companies · $8,949 in 2025
The $8,949 reported for 2025 was more than what 88% of Hematology & Oncology providers received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,500 · 2020: $1,500 · 2021: $11.92 · 2022: $24.06 · 2023: $1,880 · 2024: $5,484 · 2025: $8,949.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $12K · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $1,500 · Food and Beverage: $1,179 · Travel and Lodging: $923 · Grant: $350.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $12,360.60 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $1,500.00 |
| Food and Beverage | $1,178.96 |
| Travel and Lodging | $923.37 |
| Grant | $350.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gilead Sciences, INC. | $5,481.03 | 2021-2024 | Trodelvy |
| Astrazeneca Pharmaceuticals LP | $5,184.06 | 2024-2025 | Datroway |
| Pfizer INC. | $4,500.00 | 2019-2023 | |
| Genentech USA, INC. | $2,429.44 | 2025 | Kadcyla, Herceptin, Phesgo |
| Daiichi Sankyo INC. | $1,200.00 | 2025 | Enhertu |
| Stemline Therapeutics INC. | $318.83 | 2025 | Orserdu |
| Novartis Pharmaceuticals Corporation | $166.57 | 2025 | |
| Lilly USA, LLC | $39.40 | 2024 | Verzenio |
| Tempus Ai, INC | $29.58 | 2024 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jennifer Matro listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.